The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 30, 2020
Filed:
Aug. 24, 2015
Applicants:
Pfizer Inc., New York, NY (US);
Merck Sharp & Dohme Corp., Rahway, NJ (US);
Inventors:
Leena Das-Young, San Diego, CA (US);
Keith David Wilner, La Jolla, CA (US);
Steffan Nicholas Ho, San Diego, CA (US);
Assignees:
Pfizer Inc., New York, NY (US);
Merck Sharp & Dohme Corp., Rahway, NJ (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 31/4545 (2006.01); A61K 47/62 (2017.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39558 (2013.01); A61K 31/4545 (2013.01); A61K 47/62 (2017.08); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/3053 (2013.01); A61K 2039/505 (2013.01);
Abstract
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and an Anaplastic Lymphoma Kinase (ALK) inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that test positive for ALK, PD-L 1, or both ALK and PD-L 1.